Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Philogen S.p.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Philogen S.p.A. - Product Pipeline Review - 2014', provides an overview of the Philogen S.p.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Philogen S.p.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Philogen S.p.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Philogen S.p.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Philogen S.p.A.'s pipeline products Reasons to buy - Evaluate Philogen S.p.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Philogen S.p.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Philogen S.p.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Philogen S.p.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Philogen S.p.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Philogen S.p.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Philogen S.p.A. Snapshot 5 Philogen S.p.A. Overview 5 Key Information 5 Key Facts 5 Philogen S.p.A. - Research and Development Overview 6 Key Therapeutic Areas 6 Philogen S.p.A. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Philogen S.p.A. - Pipeline Products Glance 13 Philogen S.p.A. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Philogen S.p.A. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Philogen S.p.A. - Drug Profiles 16 Darleukin 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Fibromun 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 radretumab 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Teleukin 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Tenarad 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 F8IL-4 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Philogen S.p.A. - Pipeline Analysis 25 Philogen S.p.A. - Pipeline Products by Target 25 Philogen S.p.A. - Pipeline Products by Route of Administration 26 Philogen S.p.A. - Pipeline Products by Molecule Type 27 Philogen S.p.A. - Pipeline Products by Mechanism of Action 28 Philogen S.p.A. - Recent Pipeline Updates 29 Philogen S.p.A. - Dormant Projects 30 Philogen S.p.A. - Locations And Subsidiaries 31 Head Office 31 Other Locations & Subsidiaries 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables Philogen S.p.A., Key Information 5 Philogen S.p.A., Key Facts 5 Philogen S.p.A. - Pipeline by Indication, 2014 8 Philogen S.p.A. - Pipeline by Stage of Development, 2014 9 Philogen S.p.A. - Monotherapy Products in Pipeline, 2014 10 Philogen S.p.A. - Out-Licensed Products in Pipeline, 2014 11 Philogen S.p.A. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Philogen S.p.A. - Phase II, 2014 13 Philogen S.p.A. - Phase I, 2014 14 Philogen S.p.A. - Preclinical, 2014 15 Philogen S.p.A. - Pipeline by Target, 2014 25 Philogen S.p.A. - Pipeline by Route of Administration, 2014 26 Philogen S.p.A. - Pipeline by Molecule Type, 2014 27 Philogen S.p.A. - Pipeline Products by Mechanism of Action, 2014 28 Philogen S.p.A. - Recent Pipeline Updates, 2014 29 Philogen S.p.A. - Dormant Developmental Projects,2014 30 Philogen S.p.A., Other Locations 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.